Comprehensive genomic profiling of advanced HR+/HER2-breast cancer patients using liquid biopsy

被引：0
|
作者：
Shao, B. [1 ]
Tang, H. [2 ]
Liu, X-R.
Song, G. [1 ]
Di, L. [1 ]
Xie, F. [2 ]
Jia, C. [1 ]
Zhang, Y. [2 ]
Jia, S. [2 ]
Li, H. [1 ]
机构：
[1] Beijing Canc Hosp, Dept Breast Oncol, Beijing, Peoples R China
[2] Huidu Shanghai Med Technol Co Ltd, Translat Med, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1081
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
496P
引用
收藏
页码：S389 / S389
页数：1
相关论文
共 50 条
  • [1] The efficacy and safety of tinengotinib in patients with advanced or metastatic HR+/HER2-breast cancer or TNBC
    Sarina, Piha-Paul
    Xu, Binghe
    Fan, Ying
    Yuan, Yuan
    Lavasani, Sayeh
    Mortimer, Joanne
    Goel, Sanjay
    Tsimberidou, Apostolia
    Ibrahim, Nuhad
    Abouharb, Sausan
    Barcenas, Carlos
    Lheme, Adaeze
    Karp, Daniel
    Ahnert, Jordi Rodon
    Dumbrava, Ecaterina
    Fan, Jean
    Peng, Peng
    Sun, Caixia
    Wang, Hui
    Hennessy, Katie
    Fu, Ximei
    Xu, Ruolan
    Ni, Shumao
    Wu, Frank
    Meric-Bernstam, Funda
    CANCER RESEARCH, 2024, 84 (09)
  • [2] Everolimus and Exemestane An Innovative Therapeutic Option for Patients with advanced HR+, HER2-Breast Cancer
    Grischke, Eva-Maria
    Geberth, Matthias
    Harbeck, Nadia
    AKTUELLE NEUROLOGIE, 2014, 41 (08) : 4 - 6
  • [3] SG Improves OS in HR+/HER2-Breast Cancer
    Poh, Alissa
    CANCER DISCOVERY, 2022, 12 (12) : 2714 - 2715
  • [4] Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2-Breast Cancer
    Chang, Jenny C.
    O'Regan, Ruth
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 : S1 - S14
  • [5] Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissue
    Vollbrecht, Claudia
    Hoffmann, Inga
    Lehmann, Annika
    Merkelbach-Bruse, Sabine
    Fassunke, Jana
    Wagener-Ryczek, Svenja
    Ball, Markus
    Dimitrova, Lora
    Hartmann, Arndt
    Stohr, Robert
    Erber, Ramona
    Weichert, Wilko
    Pfarr, Nicole
    Bohlmann, Lisa
    Jung, Andreas
    Dietmaier, Wolfgang
    Dietel, Manfred
    Horst, David
    Hummel, Michael
    VIRCHOWS ARCHIV, 2023, 482 (04) : 697 - 706
  • [6] Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissue
    Claudia Vollbrecht
    Inga Hoffmann
    Annika Lehmann
    Sabine Merkelbach-Bruse
    Jana Fassunke
    Svenja Wagener-Ryczek
    Markus Ball
    Lora Dimitrova
    Arndt Hartmann
    Robert Stöhr
    Ramona Erber
    Wilko Weichert
    Nicole Pfarr
    Lisa Bohlmann
    Andreas Jung
    Wolfgang Dietmaier
    Manfred Dietel
    David Horst
    Michael Hummel
    Virchows Archiv, 2023, 482 : 697 - 706
  • [7] Clinical and economic benefit of genomic testing strategies to guide the treatment of patients with HR+/HER2-breast cancer in the US
    Gouldson, Mark
    Berdunov, Vlad
    Le, Quang Anh
    Millen, Steve
    Racz, Jennifer M.
    Arrick, Bradley A.
    Hartzfeld, Deborah
    Thakkar, Snehal Govind
    Heald, Brandie
    Russell, Christy A.
    Eymere, Sebastien
    Moyon, Camille
    Simmons, Harriet
    Carter, Gebra Cuyun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Breast Cancer CDK4/6 Inhibitors in Patients with metastatic HR+/HER2-Breast Cancer
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (1-2)
  • [9] Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2-Breast Cancer
    Kang, Connie
    TARGETED ONCOLOGY, 2024, 19 (02) : 289 - 296
  • [10] Impact of molecular subtype and race on HR+, HER2-breast cancer survival
    Reid, Sonya
    Haddad, Diane
    Tezak, Ann
    Weidner, Anne
    Wang, Xuefeng
    Mautz, Brian
    Moore, Jaleesa
    Cadiz, Sydney
    Zhu, Yuwei
    Zheng, Wei
    Mayer, Ingrid A.
    Shu, Xiao-ou
    Pal, Tuya
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (03) : 845 - 852
12345